After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

In a small phase II trial of cutaneous lupus erythematosus (CLE), patients treated with the TYK2 inhibitor had as much as 50% improvement in disease status at week 16. Adverse events in both ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

The foregoing results lead to the conclusion that patients with disseminated lupus erythematosus and some patients with rheumatoid arthritis present a delayed cutaneous hypersensitivity when ...

Medicare covers lupus treatment in different ways depending on your age and how the condition affects you. Read more.

Werth V, et al. Efficacy and safety of oral deucravacitinib in patients with cutaneous manifestations of lupus erythematosus: Results from PAISLEY CLE, a global, phase 2 randomized, double-blind ...

Systemic lupus erythematosus, or lupus, is a complex autoimmune disease ... particularly promising led to visible improvements in a clinical study in patients with cutaneous lupus after just two weeks ...